Please note that a faculty member’s research administrator will serve as the liaison on all aspects of the internal application process. If you are unsure of whom to talk to, your department contact can be found at the following link. If you pursue any grant opportunity featured in this report, please contact your research administrator first to formulate a submission plan and timeline.

The UMHS Corporate and Foundation Relations team can assist in this process, including providing direct communication with the funding entity to obtain guidance on project...
appeal/applicability to the funder, provide examples of previously funded UM proposals, and answer general faculty questions.

Please note that the funding opportunities of the Melanoma Research Alliance that were listed in the report of August 7-11, 2017 are being relisted in this report with updated URLs.

Grantor: Melanoma Research Alliance
Grant Opportunity: Research Grants
Keyword: Cancer; Chronic Diseases; Melanoma; Research Grant
Award Amount: $900,000
Deadline: October 6, 2017

Melanoma Research Alliance Team Science Awards

https://www.curemelanoma.org/research/request-for-proposals/

Awards for team science are designed to foster a collaborative research process and promote transformational melanoma research advances with the potential for rapid clinical translation.

Multidisciplinary teams of two or more established Principal Investigators and a Young Investigator with complementary expertise will receive up to $900,000 total over 3 years, to support projects with the potential to lead to transformative advances in prevention, detection, diagnosis, staging and/or treatment of melanoma.

Letters of Intent (LOIs) are due on October 6, 2017

Grantor: American Heart Association
Grant Opportunity: Research Grants
Keyword: Basic Science; Cardiovascular; Heart Attack; Stroke; Research Grant
Award Amount: $750,000
Deadline: November 1, 2017

American Heart Association Collaborative Sciences Award

http://professional.heart.org/professional/ResearchPrograms/UCM_460459_Collaborative-Sciences-Award.jsp
Statement of Purpose: To foster innovative, new collaborative approaches to research projects which propose novel pairings of investigators from at least two broadly disparate disciplines. The proposal must focus on the collaborative relationship, such that the scientific objectives could not be achieved without the efforts of at least two co-principal investigators and their respective disciplines. The combination and integration of studies may be inclusive of basic, clinical, population, behavioral, and/or translational research.

Projects that will include scientists from fields outside cardiovascular disease and stroke are highly encouraged.

Science Focus: Research broadly related to cardiovascular function and disease and stroke, or to related clinical, basic science, bioengineering or biotechnology, and public health problems, including multidisciplinary efforts.

Disciplines: Proposals are encouraged from all basic disciplines as well as epidemiological, behavioral, community and clinical investigations that bear on cardiovascular and stroke problems. AHA awards are open to the array of academic and health professionals. This includes but is not limited to all academic disciplines (biology, chemistry, mathematics, technology, physics, etc.) and all health-related professions (physicians, nurses, advanced practice nurses, pharmacists, dentists, physical and occupational therapists, statisticians, nutritionists, behavioral scientists, engineers, etc.).

Total Award Amount: $750,000

Letter of Intent Due: Nov. 1, 2017

Grantor: Foundation Fighting Blindness

Grant Opportunity: Research Grants

Keyword: Basic Science; Career Development; Chronic Diseases; Drug Discovery & Development; Genetic Disorders; Rare or Orphan Diseases; Regenerative Medicine; Research Grant; Vision, Optometry, Ophthalmology

Award Amount: $300,000

Deadline: September 29, 2017

Foundation Fighting Blindness Individual Investigator Research Grant Awards – Targeted Call for New Proposals

http://www.blindness.org/apply-for-funding

Individual Investigator Research Grant Awards are designed to concentrate research in areas that will have the greatest potential to move towards treatments and cures for the inherited orphan retinal degenerative diseases and dry age-related macular degeneration (dAMD). N.B.: FFB
does not support research for neovascular AMD or diabetic retinopathy. The Foundation has identified Research Priority Areas (RPA) that align with its mission and this targeted open call for application is to address specific gaps identified in current retinal disease research. While applications addressing the areas of particular interest below will be given priority consideration, the FFB will also consider proposals for highly novel research that do not fit easily within these goals. The LOI for such proposals must clearly explain why the research is likely to lead to prevention, treatments or cures for the orphan inherited retinal degenerative diseases.

Individual research awards are available in the following Research Priority Areas:

Novel Medical Therapies (NMT)
Gene Therapy (GT)
Cell and Molecular Mechanisms of Retinal Disease (CMM)
Genetics (GE)
Clinical-Structure and Function (CL)
Regenerative Medicine (RM)

Award: The award will be approximately $100,000 per year up to three years.

If you are interested in being considered for an award, please send a Letter of Intent (LOI) and short Curriculum Vitae (NIH Biosketch is acceptable) to FFB by September 29, 2017.

Grantor: Melanoma Research Alliance
Grant Opportunity: Research Grants
Keyword: Cancer; Chronic Diseases; Melanoma; Research Grant
Award Amount: $300,000
Deadline: November 17, 2017

Melanoma Research Alliance Established Investigator Academic-Industry Partnership Awards

https://www.curemelanoma.org/research/request-for-proposals/

These awards are designed to enhance translational research by extending academic capabilities to clinical investigations and to facilitate interactions between the academic and industrial research sectors. These awards will be co-funded by MRA and an industry partner whose involvement is essential to the project. Investigators with an established record of scientific productivity will receive up to $100,000 per year for two to three years (up to $300,000 total) from MRA to conduct projects supported by preliminary data.
Industry Partners must contact Kristen Mueller, MRA Scientific Program Director, at kmueller@curemelanoma.org by November 10, 2017, to discuss the terms of the partnership agreement. All other questions regarding the award should be directed to Tasheema Prince, Scientific Program Manager, at tprince@curemelanoma.org.

Full proposals are due on November 17, 2017. No LOI is required under Established Investigator Academic-Industry Partnership Awards

Grantor: DeGregorio Family Foundation for Gastric and Esophageal Cancer

Grant Opportunity: Research Grants

Keyword: Basic Science; Cancer; Chronic Diseases; Research Grant

Award Amount: $250,000

Deadline: November 7, 2017

8th Annual DeGregorio Foundation Award for Cancers of the Esophagus and Stomach

http://www.degregorio.org/wp/7th-annual-degregoriofoundation-award/

The DeGregorio Family Foundation for Gastric and Esophageal Cancer (www.DeGregorio.org) is pleased to announce our 8th annual funding opportunity for gastroesophageal malignancies. The Foundation seeks to promote and facilitate collaborative research on the pathogenesis, early diagnosis, and treatment of upper gastrointestinal malignancies. We support high quality, innovative, and transformative translational and bench research to improve the understanding of the biology of these diseases, identification of potential novel therapeutic targets, or in the development and evaluation of novel biomarkers for early diagnosis and treatment. Pre-clinical research, basic mechanistic studies, genomic/epigenomic studies, as well as epidemiologic studies may also be supported.

Up to $250,000 over two years will be awarded.

Deadline: November 7, 2017

Grantors: Esther A. & Joseph Klingenstein Fund and the Simons Foundation

Grant Opportunity: Research Fellowships

Keyword: Basic Science; Career Development; Neurological Disorders; Post-Doctoral Fellowship; Psychiatric

Award Amount: $225,000

Deadline: February 15, 2018
Klingenstein-Simons Fellowship Awards in the Neurosciences

http://www.klingfund.org/index.php

The Esther A. & Joseph Klingenstein Fund and the Simons Foundation announce the opening of its 2018 competition for research fellowships in the neurosciences.

Aimed at advancing cutting-edge investigations, the awards are presented to highly promising, early career scientists. At this critical juncture in young investigators' careers, when funding can be a challenge, the fellowship awards promote higher-risk, and potentially higher-reward, projects.

The Klingenstein-Simons Fellowship Awards in the Neurosciences supports, in the early stages of their careers, young investigators engaged in basic or clinical research that may lead to a better understanding of neurological and psychiatric disorders.

The Klingenstein Fund and the Simons Foundation recognize that to accomplish this goal it is necessary to encourage a variety of new approaches. Several areas within the neurosciences are of particular interest:

Cellular and molecular neuroscience—Studies of the mechanisms of neuronal excitability and development, and of the genetic basis of behavior.

Neural systems—Studies of the integrative function of the nervous system.

Translational research—Studies designed to improve the prevention, diagnosis, treatment and our understanding of the causes of neurological and psychiatric disorders.

The award of $225,000 is payable over a three-year period beginning July 1

Applications, including three letters of recommendation, are due 11:59 pm EST on February 15, 2018.

Grantor: Melanoma Research Alliance

Grant Opportunity: Career Development

Keyword: Basic Science; Cancer; Career Development; Chronic Diseases; Melanoma; Research Grant

Award Amount: $225,000

Deadline: November 17, 2017

Melanoma Research Alliance Awards for Young Investigators

https://www.curemelanoma.org/research/request-for-proposals/
Young Investigator Awards aim to attract early career scientists with novel ideas into the field of melanoma, thereby recruiting and supporting the next generation of melanoma research leaders. Awardees will be provided up to $75,000 per year for three years (up to $225,000 total) to accomplish innovative and creative, preclinical, translational, and/or early clinical research projects.

Full proposals are due on November 17, 2017. No LOI is required under Young Investigator Awards

Grantor: Melanoma Research Alliance
Grant Opportunity: Career Development
Keyword: Cancer; Career Development; Chronic Diseases; Melanoma; Research Grant; Women in Science
Award Amount: $225,000
Deadline: November 17, 2017
Special Opportunity: Melanoma Research Alliance Young Investigator Award for Women in Scientific Research

https://www.curemelanoma.org/research/request-for-proposals/

MRA is proud to offer a Young Investigator Award with the goal of attracting and supporting early career female researchers who are conducting cutting-edge melanoma research. The awardee will receive up to $225,000 total over 3 years to support projects with the potential to lead to transformative advances in prevention, detection, diagnosis, staging or treatment of melanoma.

For this Award, the PI must be a woman.

Full proposals are due on November 17, 2017. No LOI is required under Young Investigator Awards

Grantor: American Brain Tumor Association
Grant Opportunity: Research Grants
Keyword: Basic Science; Brain Cancer; Cancer; Chronic Diseases; Research Grant
Award Amount: $200,000
Deadline: September 27, 2017
American Brain Tumor Association Research Collaboration (ARC) Grant Program

http://www.abta.org/brain-tumor-research/research-grants/

ARC Grants are two year, $200,000 grants intended to promote team science in a way that will streamline and accelerate progress and affect the desired change in clinical outcome for brain tumors. Research projects supported under this mechanism must be conducted by a team of at least two co-principal investigators (Co-PI's) from distinct institutions. The research project should be multi-disciplinary in that it incorporates multiple components such as basic, translational, clinical and epidemiological research.

The ARC Grant Program requires a Letter of Intent (LOI). The ABTA Grant Application Portal is accepting these LOIs from August 16, 2017 to September 27, 2017 at noon Central Time.

Grantor: Orphan Disease Center University of Pennsylvania
Grant Opportunity: Research Grants
Keyword: Basic Science; Chronic Diseases; Genetic Disorders; Rare or Orphan Diseases;
Award Amount: $101,164
Deadline: September 18, 2017

Orphan Disease Center University of Pennsylvania 2017 Million Dollar Bike Ride Pilot Grant Program: Request for Applications

http://www.med.upenn.edu/orphandisease/rare-disease-overview.html

The 2017 Million Dollar Bike Ride Pilot Grant Program is now open! The MDBR Pilot Grant Program provides a one-year grant to support research related to a rare disease represented in the 2017 Million Dollar Bike Ride.

Research Focus Areas for Pilot Grants:

1) Adrenoleukodystrophy (ALD): One $101,164 pilot grant is available with a focus on a path towards treatment for Adrenomyeloneuropathy (AMN). Grants should focus on activities that lead towards a clinical trial.

2) Adult Polyglucosan Body Disease (APBD): Two $52,978 grants are available to initiate or advance research of a treatment or a cure for this glycogen storage disease.

3) Ataxia-Telangiectasia: One $65,689 grant is available to identify and test therapeutic strategies for the neurodegeneration and motor control problems faced by patients affected by Ataxia-Telangiectasia. Projects may involve early, preclinical studies such as target
identification, phenotypic screening, gene therapy vectors or the elucidation of disrupted neurocircuitry but must be novel and have a clear path for translation to a therapy.

4) BPAN- A Neurodegeneration with Brain Iron Accumulation Disorder: Two $50,507 pilot grants are available for clinical and translational research studies related to the detection, diagnosis, or treatment of this rare, X-linked disorder caused by mutations in WDR45. Grants are expected to generate essential resources for the scientific community, advance knowledge about BPAN disease processes, and produce preliminary data to enable national and international funding to carry the work forward. Examples of priority topic areas include developing disease models that complement existing models, identifying biomarkers, delineating the molecular cascade that leads to early cellular changes, developing rational therapeutics, establishing outcome measures to be used in clinical trials, and developing other essential resources to substantially prepare the BPAN community for clinical trials. Natural history studies must have a component that includes participation in the International NBIA Patient Registry & Biobank.

5) Castleman Disease: A $42,508 pilot grant is available to perform critical investigations into the etiology and pathogenesis of HHV-8-negative/"idiopathic" multicentric Castleman disease (iMCD). We seek to fund research that will improve understanding of the etiology, genomic aberrations, aberrant cell populations, dysregulated signaling pathways, and/or effector cytokines in iMCD.

6) CDKL5: Two $51,160 grants are available, made possible by The International Foundation for CDKL5 Research and Team CDKL5.

CDKL5 Postmortem Brain Samples ($51,160): Research focused on genetic, molecular and anatomical studies of postmortem brain samples of CDKL5. There are CDKL5 postmortem samples at the Harvard Brain Bank under the Rett Syndrome special collection. This area is completely underrepresented in any current CDKL5 research, and can inform the future of other aspects of CDKL5 research. IFCR will assist the awardee with gaining access to this tissue.

Mechanisms of CDKL5 Seizure Activity ($51,160): Research focused on seizures in CDKL5, including but not limited to causation, treatment, or evaluation. This can include drug screening.

7) Congenital Hyperinsulinism (CHI): One $87,109 grant available for an innovative, pre-clinical or clinical study that has the potential to lead to: (1) faster and more accurate diagnoses of congenital hyperinsulinism (HI); (2) better HI treatment; (3) a cure for HI; or (4) quality of life improvement for those affected by HI.

8) Congenital Muscular Dystrophy (CMD): One $41,831 grant available. The purpose of this RFA is to promote discovery of underlying disease mechanisms and preclinical development of potential therapies, as well as the clinical translation of those efforts. Areas of interest include, but are not limited to, understanding the cause of disease, unraveling pathways involved in disease, identifying novel drug targets or gene therapies, and testing new strategies to treat disease or any of its incapacitating consequences (e.g. contractures). In addition, applications
may propose to create or improve disease models (e.g. animal models, patient-derived cell models), biomarkers or functional outcome measures to assess therapeutic impact. Priority will be given to research projects targeting Collagen VI (Ullrich).

9) CRB1 degenerative retinal disease: Two $50,497 grants are available for work toward treatments for CRB1 retinal disease. Applications including gene therapy, CRISPR, cell therapy or other methods that will halt the progression of CRB1 retinal disease and ultimately restore retinal function will be considered.

10) Nonsense Mutations in Cystic Fibrosis: One $52,985 grant available. The grant will be awarded to advance research and understanding of a treatment or cure that would impact people carrying a nonsense mutation. The research should include, but not be limited to, the R1158X gene mutation.

11) Dyskeratosis Congenita & Telomere Biology Disorder: One $48,191 pilot grant available to investigators conducting clinical studies or basic science research on all aspects of Dyskeratosis Congenita or Telomere Biology Disorders. Proposals that seek to advance understanding of the manifestations of the disease will be considered. This research could involve the examination of late effects of the disease—including late effects of stem cell transplant; the development of a comprehensive database that characterizes clinical complications and or treatments; focus on gene discovery; or address any of the unmet needs of DC/TBD patients.

12) Fibrous Dysplasia/McCune Albright Syndrome: Two grants available, each for up to $53,614. Any study that focuses on the pathogenesis of FD/MAS, or clinical investigative studies to address any of the unmet needs in FD/MAS patients and their management will be considered. Research priorities for the Fibrous Dysplasia Foundation include: generation of new mouse models to study FD/MAS; studies to understand the mechanism and/or treatment of FD-related bone pain; development/testing of therapeutics, especially those targeting Gsα, PKA or Wnt signaling pathways, including through the use of oligonucleotides; or studies of the molecular etiology, especially the role of RANKL, IL6, cAMP and FGF23.

13) Generalized Lymphatic Anomaly (GLA; a.k.a. lymphangiomatosis) and Gorham-Stout Disease (GSD): Two grants are available for basic science and/or clinical research on GSD or GLA. One is for $80,185 and the other is for $52,109. Areas of interest include, but are not limited to, genetic analysis, biomarker identification, cell line creation and characterization, and imaging.

14) Glucose Transporter Deficiency Syndrome (Glut 1DS): One $47,519 pilot grant is available and will be awarded to research focused on identifying and investigating innovative research projects that involve basic research including blood brain barrier, translational studies, clinical studies, alternative treatment theory, or gene therapy relevant to Glut 1DS.

15) Lymphangioleiomyomatosis (LAM): Two $50,060 pilot grants will be available focusing on translational proposals with strong likelihood of future federal funding, that use LAM samples, models or patient data, and which have the potential to favorably impact human health will be given priority. Examples of desirable topic areas include identification of molecular targets,
biomarker development, and biomarker driven small pilot trials. In 2017, LAM research grant proposals from early career investigators (three years or less into their first faculty appointment) who are working in the laboratories of established LAM researchers or conducting research with the mentorship of established LAM researchers will be given priority.

16) Mucolipidosis Type IV (ML4): One $71,939 pilot grant available. We offer this grant to investigators conducting research on all aspects of disease including disease pathogenesis and clinical studies. Preference will be given to those research projects developing new therapies for MLIV, and translational research projects that improve our understanding of the disease state and pathogenesis, such as biomarkers or functional outcome measures to assess therapeutic impact.

17) Mucopolysaccharidoses (MPS): Two $59,449 pilot grants available. Mucopolysaccharidoses represent a broad array of diseases due to enzyme defects that lead to abnormal metabolic storage products and multi-organ pathologies. We are seeking applications directed to treating the central nervous system manifestations or antibody response of these diseases.

18) Niemann Pick Type C (NPC): Two $49,645 pilot grants available. Consideration will be given to research projects developing new therapies for NPC as well as those designed to complement therapies presently in the pipeline. Consideration will further be given to gene therapy proposals; studies focused on problems, including psychiatric issues, impacting quality of life through the lifespan of the patient population and research projects that improve our understanding of the biology, pathogenesis and disease state (i.e., biomarkers or functional outcome measures to assess therapeutic impact) and have a direct impact on translation of new treatments to patients.

19) Pitt Hopkins Syndrome (PTHS): Two $49,263 pilot grants available. The Pitt Hopkins Research Foundation would like to focus this research on finding therapeutics and a cure for this debilitating syndrome and are not interested in natural history studies at this time.

20) RASopathies: One $47,189 pilot grant available. This grant should be directed toward the development of a treatment or cure for the RASopathies, and must include NS, CFC, and CS.

21) Snyder-Robinson Syndrome: Two $42,866 grants are available for Snyder-Robinson Syndrome. Research focus includes further understanding of pathophysiology and/or mechanisms by which SRS causes disease as well as potential treatments, which will cure and/or improve quality of life of those with SRS.

22) Tay-Sachs, Sandhoff, GM-1, or Canavan Disease: One $42,419 pilot grant is available focusing on forms of Tay-Sachs, Sandhoff, GM-1, or Canavan disease. We are soliciting proposals for innovative research projects that involve basic research, translational studies or clinical studies relevant to the diseases mentioned above.

Interested applicants must first submit a Letter of Interest (LOI). This LOI is due by Monday, September 18, 2017 by 8pm EST.
Grantor: American Brain Tumor Association
Grant Opportunity: Research Grants
Keyword: Basic Science; Brain Cancer; Cancer; Chronic Diseases; Post-Doctoral Fellowship
Award Amount: $100,000
Deadline: September 27, 2017

American Brain Tumor Association Basic Research Fellowship Program

http://www.abta.org/brain-tumor-research/research-grants/

Basic Research Fellowship Grants are two year, $100,000 grants supporting postdoctoral fellows conducting brain tumor research. Fellows must include a lead mentor who currently conducts brain tumor research at the same academic institution in an effort to provide research, scientific management and other leadership guidance necessary to foster the applicant’s career advancement.

The ABTA Grant Application Portal is accepting Basic Research Fellowship LOIs from August 16, 2017 to September 27, 2017 at noon Central Time.

Grantor: Promobilia Foundation
Grant Opportunity: Research Grants
Keyword: Assistive Technology; Neuromuscular Disorders; Research Grant
Award Amount: $100,000
Deadline: October 12, 2017

Promobilia Foundation Grants for Research and Development Projects

http://www.promobilia.se/?lang=en

The aim of the Foundation is to promote the development of technical aids so that disabled persons could benefit of a more active life. Our task is to support research and development of technical aids as well as ensure they get into production and reach the needy.

The Foundation mainly gives support for development of tools for mobility handicapped but has also supported research about the comprehension of reading and writing difficulties. The Foundation has also supported research around diseases that could lead to severe motion problems.
Grants for research- and development projects: The Foundation Promobilia set aside founds to support research and development projects. The Foundation Promobilia supports research and development projects. We give grants in the range of SEK 100,000 – 500,000 (in USD about 10,000 – 100,000).

Applications shall be posted to Promobilia not later than Thursday, October 12th 2017

Grantor: Foundation Fighting Blindness

Grant Opportunity: Fellowships

Keyword: Career Development; Chronic Diseases; Genetic Disorders; Post-Doctoral Fellowship; Rare or Orphan Diseases; Vision, Optometry, Opthalmology

Award Amount: $65,000

Deadline: September 29, 2017

Request for Applications: Clinical/Research Fellowship Award Program in Inherited Orphan Retinal Degenerations

http://www.blindness.org/apply-for-funding

The Foundation Fighting Blindness (FFB) is soliciting applications for Clinical/Research Fellowship Awards (CRFA) from clinicians with a demonstrated interest in inherited orphan retinal degenerations. The program will provide funding for post-residency clinical fellowships in inherited orphan retinal degenerations. The goal of this program is to increase the number of clinician-scientists with expertise and commitment to provide clinical care to patients with inherited orphan retinal degenerations. With this goal in mind, the program is also designed to prepare fellows for careers in academic medicine, providing critical training in an environment that fosters research to develop preventions, treatments, and cures for inherited orphan retinal degenerations.

Award: Up to three awards are available (for this fiscal year, FY17). In general, each one-year award will be for a total of $65,000.

Application Deadline: September 29, 2017

Grantor: American Brain Tumor Association

Grant Opportunity: Research Grants

Keyword: Basic Science; Brain Cancer; Cancer; Chronic Diseases; Research Grant

Award Amount: $50,000
American Brain Tumor Association Discovery Grant Program

http://www.abta.org/brain-tumor-research/research-grants/

Discovery Grants are one year, $50,000 grants for investigators conducting high-risk/high-impact research deemed to have the potential to change current diagnostic or treatment paradigms. Investigators should be full-time faculty to apply.

The Discovery Grant Program requires a LOI. The ABTA Grant Application Portal is accepting these LOIs from August 16, 2017 to September 27, 2017 at noon Central Time.

Grantor: Cures Within Reach
Grant Opportunity: Research Grants
Keyword: Cancer; Chronic Diseases; Research Grant
Award Amount: $50,000
Deadline: September 22, 2017

Call for Proposals: CureAccelerator Live

https://app.cureaccelerator.org/home

CureAccelerator Live! is a networking/pitch event held in Chicago on Nov. 15, where teams of researchers and/or clinicians present their repurposing research ideas. By the end of the evening, at least one team/project is selected for funding!

This year, CureAccelerator Live has a cancer focus. We're looking for repurposing clinical trials that either:

Repurpose therapies to treat unsolved cancers or unmet cancer needs
Repurposing cancer therapies for a non-cancer disease

Up to $50,000 per project is available, and at least one project will be funded. The deadline for the RFP is September 22, and researchers are asked to submit a project proposal on CureAccelerator. If selected to participate in the pitch event, the PI will be required to travel to Chicago, and there are currently no travel stipends or reimbursements available.

Grantor: Pablove Foundation
Grant Opportunity: Seed Grants
Keyword: Basic Science; Cancer; Chronic Diseases; Pediatric Cancers; Research Grant
Award Amount: $50,000
Deadline: October 19, 2017

Request for Applications: Pablove Foundation Childhood Cancer Research Seed Grants

https://proposalcentral.altum.com/opportunities.asp?GMID=139

The Pablove Foundation invests in underfunded, cutting-edge pediatric cancer research, and improves the lives of children living with cancer through the arts. Our mission is built on our impassioned desire to find a cure, and to allow kids living with cancer to still be kids while undergoing treatment.

What We Fund The Pablove Foundation is interested in principal investigators who will join us in taking risks, pushing for new solutions, and harnessing the transformative power of science in their research in the following areas, with preferences going toward less common childhood cancers:

- Mechanisms of Disease
- Genetics
- Preclinical Models
- Biomarkers and Surrogate Markers
- Prognostic Factors
- Diagnosis
- Innovative Clinical Therapeutic Trials
- Minimal Residual Disease Detection
- Treatment
- Supportive Care and Prevention
- Amelioration of Long-Term Effects of Therapy

In addition, projects that focus on Opsoclonus-Myoclonus Syndrome (OMS) will be considered.

The Seed Grants provides $50,000 for 1 year of funding. Grantees who wish to continue gathering preliminary data to prepare for support past the seed stage may apply for an additional year of funding. Please note that this funding is not guaranteed; a second year of funding may be granted based on exemplary scientific progress, availability of funds, and competitiveness with the incoming class of new grant applicants. In addition, no cost extensions may be granted on an individual basis with specific written request.
LOIs must be submitted by October 19, 2017 at 5:00 p.m. Eastern Time (US).

Grantor: Laura and John Arnold Foundation
Grant Opportunity: Research Grants
Keyword: Health Policy & Research; Public Health; Under-represented Populations
Award Amount: Not Specified
Deadline: October 1, 2017

Requests for Proposal: Randomized Controlled Trials to Test Interventions for Frequent Utilizers of Multiple Health, Criminal Justice, and Social Service Systems

http://www.arnoldfoundation.org/request-for-proposals/

Letters of Interest (LOI) will be accepted on a rolling basis through Oct. 1, 2017.

Grantor: Foundation Fighting Blindness
Grant Opportunity: Research Grants
Keyword: Basic Science; Chronic Diseases; Genetic Disorders; Rare or Orphan Diseases; Research Grant; Vision, Optometry, Ophthalmology
Award Amount: Not Specified
Deadline: September 29, 2017

Foundation Fighting Blindness Program Project Award

http://www.blindness.org/apply-for-funding

The PPA is designed to support collaborative, multi-disciplinary, research studies that engage investigators with different expertise and resources. The PPA is intended to enable studies that are too large or complex for a single investigator to undertake in a reasonable amount of time and to address gaps in our current knowledge or therapeutic options. The PPA must be unified around a single, well-articulated hypothesis and a clearly defined deliverable(s), relevant to the mission of FFB. The teams supported by a PPA must be tightly integrated and sharply focused, freely share data and creative ideas, and each be essential to the common goal.

The PPA is not intended to support clinical research unless it is tightly integrated with the other projects and the PPA is not intended to support research cores.
Inherited Retinal Degeneration Disease(s) that this Research will Impact Includes Retinitis Pigmentosa, Bardet-Biedl, Bestrophin Disease, Blue-cone Monochromacy, Cone-Rod Dystrophy, Choroideremia, dry Age-related Macular Degeneration, Leber Congenital Amaurosis, Refsum, Retinoschisis, Stargardt, Usher Syndrome.

Applicants must submit the completed LOI electronically by September 29, 2017 11:59PM EDT via the FFB Application Portal.